Literature DB >> 24893836

Three midlife strategies to prevent cognitive impairment due to Alzheimer's disease.

V W Henderson1.   

Abstract

The slow, progressive accumulation of pathology characteristic of Alzheimer's disease is the principal determinant of cognitive decline leading to dementia. Risk-reduction strategies during midlife focus on raising the clinical threshold for the appearance of cognitive symptoms and on reducing the extent of Alzheimer pathology. Best available evidence suggests an approach based on three, conceptually distinct strategies. (1) Raise the threshold for cognitive symptoms by improving brain health. To achieve this goal, the tactic is to reduce cerebrovascular risks mediated by hypertension, diabetes, cigarette smoking, and hyperlipidemia. (2) Raise the threshold for cognitive symptoms by enhancing cognitive reserve. Here, tactics focus on mental stimulation associated with occupation, leisure activities and social engagement. (3) Reduce the burden of Alzheimer pathology. The most promising tactic toward this end is regular aerobic exercise. Tactics in support of strategies to reduce cognitive impairment due to Alzheimer pathology are not yet substantiated by robust, consistent clinical trial evidence. There is pressing need for well-designed pragmatic trials to provide stronger evidence on preventive strategies for late-life cognitive decline and dementia.

Entities:  

Keywords:  ALZHEIMER'S DISEASE; COGNITIVE IMPAIRMENT; COGNITIVE RESERVE; MIDLIFE; PHYSICAL ACTIVITY; PREVENTION

Mesh:

Substances:

Year:  2014        PMID: 24893836      PMCID: PMC4236238          DOI: 10.3109/13697137.2014.929650

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  104 in total

Review 1.  Physical activity and risk of cognitive decline: a meta-analysis of prospective studies.

Authors:  F Sofi; D Valecchi; D Bacci; R Abbate; G F Gensini; A Casini; C Macchi
Journal:  J Intern Med       Date:  2010-09-10       Impact factor: 8.989

Review 2.  Structural brain changes in aging: courses, causes and cognitive consequences.

Authors:  Anders M Fjell; Kristine B Walhovd
Journal:  Rev Neurosci       Date:  2010       Impact factor: 4.353

Review 3.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

Review 4.  Statins for the treatment of dementia.

Authors:  Bernadette McGuinness; John O'Hare; David Craig; Roger Bullock; Reem Malouf; Peter Passmore
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

Review 5.  Gender, sex steroid hormones, and Alzheimer's disease.

Authors:  Rebekah S Vest; Christian J Pike
Journal:  Horm Behav       Date:  2012-04-19       Impact factor: 3.587

Review 6.  Depression and risk of developing dementia.

Authors:  Amy L Byers; Kristine Yaffe
Journal:  Nat Rev Neurol       Date:  2011-05-03       Impact factor: 42.937

Review 7.  Sleep and Alzheimer disease pathology--a bidirectional relationship.

Authors:  Yo-El S Ju; Brendan P Lucey; David M Holtzman
Journal:  Nat Rev Neurol       Date:  2013-12-24       Impact factor: 42.937

8.  Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

Authors:  C G Lyketsos; J C S Breitner; R C Green; B K Martin; C Meinert; S Piantadosi; M Sabbagh
Journal:  Neurology       Date:  2007-04-25       Impact factor: 9.910

9.  Molecular mechanism for age-related memory loss: the histone-binding protein RbAp48.

Authors:  Elias Pavlopoulos; Sidonie Jones; Stylianos Kosmidis; Maggie Close; Carla Kim; Olga Kovalerchik; Scott A Small; Eric R Kandel
Journal:  Sci Transl Med       Date:  2013-08-28       Impact factor: 17.956

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  5 in total

1.  Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers.

Authors:  Timothy C Durazzo; Magdalena Korecka; John Q Trojanowski; Michael W Weiner; Ruth O' Hara; John W Ashford; Leslie M Shaw
Journal:  J Alzheimers Dis       Date:  2016-07-25       Impact factor: 4.472

Review 2.  Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta-analysis.

Authors:  P Lehert; P Villaseca; E Hogervorst; P M Maki; V W Henderson
Journal:  Climacteric       Date:  2015-09-11       Impact factor: 3.005

3.  Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.

Authors:  Siobhan M Hoscheidt; Erika J Starks; Jennifer M Oh; Henrik Zetterberg; Kaj Blennow; Rachel A Krause; Carey E Gleason; Luigi Puglielli; Craig S Atwood; Cynthia M Carlsson; Sanjay Asthana; Sterling C Johnson; Barbara B Bendlin
Journal:  J Alzheimers Dis       Date:  2016-04-12       Impact factor: 4.472

4.  The NEIL Memory Research Unit: psychosocial, biological, physiological and lifestyle factors associated with healthy ageing: study protocol.

Authors:  Caoimhe Hannigan; Robert F Coen; Brian A Lawlor; Ian H Robertson; Sabina Brennan
Journal:  BMC Psychol       Date:  2015-06-27

5.  Impact of sociodemographic variables on executive functions.

Authors:  Kenia Repiso Campanholo; Izadora Nogueira Fonte Boa; Flávia Cristina da Silva Araujo Hodroj; Glaucia Rosana Benute Guerra; Eliane Correa Miotto; Mara Cristina Souza de Lucia
Journal:  Dement Neuropsychol       Date:  2017 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.